万达生物制药(VNDA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VNDA 万达生物制药

未开盘 12-20 16:00:00 EST

4.78

+0.15

+3.24%

盘后4.78

+0.000.00%

17:12 EST

最高4.83	最低4.59	成交量92.64万
今开4.59	昨收4.63	日振幅5.18%
总市值2.79亿	流通市值2.52亿	总股本5,831万
成交额439.11万	换手率1.76%	流通股本5,262万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"VNDA","market":"US","secType":"STK","nameCN":"万达生物制药","latestPrice":4.78,"timestamp":1734728400000,"preClose":4.63,"halted":0,"volume":926409,"hourTrading":{"tag":"盘后","latestPrice":4.78,"preClose":4.78,"latestTime":"17:12 EST","volume":31458,"amount":150368.841,"timestamp":1734732770612},"delay":0,"floatShares":52621723,"shares":58308144,"eps":-0.290167,"marketStatus":"未开盘","marketStatusCode":0,"change":0.15,"latestTime":"12-20 16:00:00 EST","open":4.59,"high":4.83,"low":4.59,"amount":4391086.0191,"amplitude":0.051836,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.290167,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":0,"listingDate":1144814400000,"adjPreClose":4.63,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":4.6299,"preClose":4.63,"latestTime":"09:29 EST","volume":10874,"amount":52304.468476,"timestamp":1734704994967},"postHourTrading":{"tag":"盘后","latestPrice":4.78,"preClose":4.78,"latestTime":"17:12 EST","volume":31458,"amount":150368.841,"timestamp":1734732770612},"volumeRatio":1.667926361484592,"impliedVol":0.2072,"impliedVolPercentile":0.0357},"requestUrl":"/m/hq/s/VNDA","defaultTab":"news","newsList":[{"id":"2490704950","title":"Vanda Pharmaceuticals Inc.盘中异动 大幅下挫5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490704950","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490704950?lang=zh_cn&edition=full","pubTime":"2024-12-11 01:29","pubTimestamp":1733851771,"startTime":"0","endTime":"0","summary":"北京时间2024年12月11日01时29分，Vanda Pharmaceuticals Inc.股票出现异动，股价快速跳水5.08%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体跌幅为1.11%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211012931984b14e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211012931984b14e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"2486878043","title":"Vanda Pharmaceuticals Inc.盘中异动 大幅上涨5.02%报5.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486878043","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486878043?lang=zh_cn&edition=full","pubTime":"2024-11-27 22:53","pubTimestamp":1732719236,"startTime":"0","endTime":"0","summary":"北京时间2024年11月27日22时53分，Vanda Pharmaceuticals Inc.股票出现异动，股价大幅拉升5.02%。截至发稿，该股报5.23美元/股，成交量11.3383万股，换手率0.19%，振幅3.61%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.11%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127225357971a8e4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127225357971a8e4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"2483730989","title":"Vanda Pharmaceuticals Inc.2024财年第三财季实现净利润-5.32百万美元，同比减少3983.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483730989","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483730989?lang=zh_cn&edition=full","pubTime":"2024-11-16 00:00","pubTimestamp":1731686420,"startTime":"0","endTime":"0","summary":"11月16日，Vanda Pharmaceuticals Inc.公布财报，公告显示公司2024财年第三财季净利润为-5.32百万美元，同比减少3983.21%；其中营业收入为47.65百万美元，同比增加22.75%，每股基本收益为-0.09美元。从资产负债表来看，Vanda Pharmaceuticals Inc.总负债1.04亿美元，其中短期债务2.45百万美元，资产负债比为6.21，流动比率为0.05。机构评级：截至2024年11月16日，当前有3家机构对Vanda Pharmaceuticals Inc.目标价做出预测，其中目标均价为12.17美元，其中最低目标价为5.50美元，最高目标价为18.00美元。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000046abc513a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000046abc513a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA"],"gpt_icon":0},{"id":"2481355180","title":"Vanda Pharmaceuticals Inc.盘中异动 早盘股价大涨5.01%报5.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481355180","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481355180?lang=zh_cn&edition=full","pubTime":"2024-11-07 23:25","pubTimestamp":1730993159,"startTime":"0","endTime":"0","summary":"北京时间2024年11月07日23时25分，Vanda Pharmaceuticals Inc.股票出现异动，股价快速上涨5.01%。截至发稿，该股报5.14美元/股，成交量22.9074万股，换手率0.39%，振幅6.65%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107232559a221095f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107232559a221095f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"2481552732","title":"旺达制药公司  预计每股亏损16美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2481552732","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481552732?lang=zh_cn&edition=full","pubTime":"2024-11-05 05:19","pubTimestamp":1730755147,"startTime":"0","endTime":"0","summary":"   * Vanda Pharmaceuticals Inc    将于11月6日公布截至2024年9月30日的财报，预计季度收入将有所增长。* 根据LSEG的数据，3位分析师的平均预期显示，这家总部位于华盛顿特区的公司的营收有望从去年同期的3882万美元增长26.6%，达到4915.5万美元。* LSEG 分析师对 Vanda Pharmaceuticals Inc 的平均预期是每股亏损 16 美分。* 华尔街对 Vanda Pharmaceuticals Inc 的 12 个月目标价中位数为 9.50 美元，高于其上次收盘价 4.66 美元。11月4日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"旺达制药公司  预计每股亏损16美分 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA"],"gpt_icon":0},{"id":"2479003459","title":"Vanda Pharmaceuticals Inc.盘中异动 临近收盘急速拉升5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479003459","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479003459?lang=zh_cn&edition=full","pubTime":"2024-10-29 03:35","pubTimestamp":1730144113,"startTime":"0","endTime":"0","summary":"北京时间2024年10月29日03时35分，Vanda Pharmaceuticals Inc.股票出现异动，股价大幅上涨5.05%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体跌幅为0.05%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102903351398e3ee5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102903351398e3ee5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"2475392524","title":"BUZZ--美国股票走势-Adobe、BigBear.ai、PG&E","url":"https://stock-news.laohu8.com/highlight/detail?id=2475392524","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475392524?lang=zh_cn&edition=full","pubTime":"2024-10-15 00:11","pubTimestamp":1728922264,"startTime":"0","endTime":"0","summary":"    路透10月14日 - 标普500指数和纳斯达克指数周一上涨，基准指数盘中创下历史新高，投资者为本周的企业财报和重要经济数据做好了准备，这些数据可能会对股市紧张的估值构成考验。美东时间上午11:33，道琼斯公司  指数上涨0.3%，报42,977.41点。标普500指数  上涨0.58%，报5848.9点；纳斯达克综合指数  上涨0.75%，报18480.636点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e0d2f042c4e70b32b31caa57119ceaee","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADBE","BBAI","WYNN","RILY","DECK","WDC","PSQ","LRCX","DDM","SIRI","FANG","VNDA","NDAQ","NEXT","EXPD","SQQQ","LUV","CNX","LBPH",".IXIC","CAT","BUSE","KLAC","RIOT","AMAT","JSPR","TGI","NQmain","DJX",".DJI","MARA","HUT",".SPX","COIN","ULTA","XOM","VFC","MNQmain","L","QLD","ACGL","EQT","2NVD.UK"],"gpt_icon":1},{"id":"2475943143","title":"更新版 1-万达制药公司拒绝循环制药公司的第二次收购要约","url":"https://stock-news.laohu8.com/highlight/detail?id=2475943143","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475943143?lang=zh_cn&edition=full","pubTime":"2024-10-14 23:53","pubTimestamp":1728921238,"startTime":"0","endTime":"0","summary":"     路透10月14日 - 万达制药  周一拒绝了英国Cycle Pharmaceuticals公司的第二份收购建议，尽管在FDA否决了其胃病药物后万达股价下跌，但该建议对这家制药商的估值为每股8美元。背景 万达于4月通过了 ，一项被称为 \"毒丸 \"的股东权利计划，以降低恶意收购的可能性。关键语录 万达表示，公司董事会仔细审查了第二项提案，\"一致认为该提案严重低估了万达的价值，不符合公司及其股东的最佳利益\"。市场反应 万达股价上涨 11.37%，报 4.95 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"2475393577","title":"循环制药公司维持对旺达制药公司的收购要约","url":"https://stock-news.laohu8.com/highlight/detail?id=2475393577","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475393577?lang=zh_cn&edition=full","pubTime":"2024-10-14 22:34","pubTimestamp":1728916491,"startTime":"0","endTime":"0","summary":"Vanda在6月份拒绝了Cycle Pharma提出的  收购要约和合同制造商Future Pak提出的修改后的收购要约。重要原因 Cycle提出以每股8美元的价格收购万达，比万达上一次收盘价高出80%。此前，美国食品和药物管理局拒绝 ，批准其治疗胃部消化紊乱疾病的药物，Vanda的股价下跌了4.5%。背景 万达于四月通过了  一项股东权利计划，即 \"毒丸\"，以降低恶意收购的可能性。市场反应 万达股价上涨 12.3%，报 4.99 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"2475362578","title":"Vanda Pharmaceuticals Inc.股价拉升14.64% 市值涨4343.53万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2475362578","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475362578?lang=zh_cn&edition=full","pubTime":"2024-10-14 21:31","pubTimestamp":1728912662,"startTime":"0","endTime":"0","summary":"北京时间2024年10月14日21时31分，Vanda Pharmaceuticals Inc.股票出现异动，股价急速上涨14.64%。截至发稿，该股报5.09美元/股，成交量145.229万股，换手率2.49%，振幅2.02%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.08%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410142131029f41ca0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410142131029f41ca0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"2475361809","title":"BUZZ-周期制药公司重申收购要约，万达跳涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2475361809","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475361809?lang=zh_cn&edition=full","pubTime":"2024-10-14 21:05","pubTimestamp":1728911159,"startTime":"0","endTime":"0","summary":"** Cycle表示，该收购方案与10月11日的万达股价相比溢价80%，而与2024年6月5日的股价相比溢价58%，2024年6月5日是Cycle首次公开收购要约的前一天。** Cycle 于 6 月  6 日以每小时 8 美元的价格提出收购要约，但遭到万达拒绝。 ** 该公司还在 9 月份发出了一份重申要约的建议书，但也于 10 月 7 日被万达拒绝。** 截至上次收盘，股价年累计上涨 5.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"2475514683","title":"媒体-据说 Cycle Pharma 将坚持以 4.88 亿美元收购 Vanda - 彭博新闻社","url":"https://stock-news.laohu8.com/highlight/detail?id=2475514683","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475514683?lang=zh_cn&edition=full","pubTime":"2024-10-14 18:33","pubTimestamp":1728902024,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    10月14日 - -- 来源链接：  -- 注：路透未核实此报导，不保证其准确性","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"2475351457","title":"媒体-据说 Cycle Pharma 将坚持以 4.88 亿美元收购 Vanda - 彭博新闻社","url":"https://stock-news.laohu8.com/highlight/detail?id=2475351457","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475351457?lang=zh_cn&edition=full","pubTime":"2024-10-14 18:33","pubTimestamp":1728902024,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    10月14日 - -- 来源链接：  -- 注：路透未核实此报道，不保证其准确性","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"2470703554","title":"更新版 3-更正-百时美施贵宝公司新型精神分裂症药物获美国 FDA 批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2470703554","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470703554?lang=zh_cn&edition=full","pubTime":"2024-09-27 07:04","pubTimestamp":1727391881,"startTime":"0","endTime":"0","summary":"更新版 3-更正-百时美施贵宝公司新型精神分裂症药物获美国 FDA 批准周五盘前股价上涨 6新型精神分裂症治疗药物获得 FDA 批准布里斯托尔公司将药物定价为每月 1,850 美元更新 9 月 26 日的报道，在第 2 段和第 3 段增加了有关其他抗精神病药物的细节，在第 4 段增加了有关股票的细节Bhanvi Satija/Michael Erman. FDA 批准该药的依据是两项研究的数据，在这两项研究中，服用该药的患者症状明显减轻。精神分裂症会导致持续的妄想和幻觉，严重影响患者对现实的感知。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240926:nL4S3L823P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310800379.SGD","LU0211327993.USD","LU0211328371.USD","VNDA","LU1093756325.SGD","LU1057294990.SGD","BK4559","IE0004445239.USD","LU0128525929.USD","LU0320765992.SGD","IE0002141913.USD","LU0225284248.USD","LU1989771016.USD","LU0256863811.USD","LU2242652126.USD","BMY","LU1244550221.USD","LU0203347892.USD","ABBV","BK4139","LU0708994859.HKD","LU1670710588.SGD","IE00BJT1NW94.SGD","LU1023059063.AUD","LU0061475181.USD","LU0310799852.SGD","BK4566","LU0553294199.USD","BK4007","LU1571399168.USD","LU0795875169.SGD","NBIX","LU1261432733.SGD","LU0985481810.HKD","IE00BJJMRZ35.SGD","BK4581","BK4532","LU0943347566.SGD","LU1061106388.HKD","LU0122379950.USD","LU1074936037.SGD","LU1585245621.USD","LU0225771236.USD","LU0868494617.USD","LU0237698245.USD","LU0114720955.EUR","LU0321505868.SGD","LU1093756168.USD","LU1003077747.HKD","LU0882574055.USD"],"gpt_icon":0},{"id":"2470446910","title":"Vanda Pharmaceuticals Inc.盘中异动 下午盘大幅拉升5.05%报4.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2470446910","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470446910?lang=zh_cn&edition=full","pubTime":"2024-09-25 03:17","pubTimestamp":1727205471,"startTime":"0","endTime":"0","summary":"北京时间2024年09月25日03时17分，Vanda Pharmaceuticals Inc.股票出现异动，股价大幅上涨5.05%。截至发稿，该股报4.99美元/股，成交量56.0561万股，换手率0.96%，振幅7.89%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体跌幅为0.62%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092503175298e38b70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092503175298e38b70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"2468042765","title":"BUZZ--美国股票走势-Spotify、Coursera、Tandem 糖尿病护理公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2468042765","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468042765?lang=zh_cn&edition=full","pubTime":"2024-09-20 00:05","pubTimestamp":1726761931,"startTime":"0","endTime":"0","summary":"        *      Eikon 个股走势搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      9月19日 - 在美联储以削减半个百分点开启宽松周期并预测将有更多削减后，华尔街周四反弹，标普500指数再创盘中纪录新高。美东时间11:34，道琼斯工业平均指数  上涨1.02%，报41,927.77点。标普500指数  上涨1.66%，报5711.6点；纳斯达克综合指数  上涨2.66%，报18040.538点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COUR","VNDA","FDS","ELAN","ANGL","3NVD.UK","MBLY","IEF","CRMT","TNDM","CRK","LEN",".DJI","UDOW","SQQQ","DJX","FITB","KEY","LU",".IXIC","PHM","TGT","DRI","EWTX","DHI","BANC","KBH","HESM","NQmain","SPOT","TQQQ","AHR","2NVD.UK","VST","DASH","TOL","DOG","DXD"],"gpt_icon":1},{"id":"2468570571","title":"Vanda Pharmaceuticals Inc.盘中异动 大幅下跌9.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2468570571","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468570571?lang=zh_cn&edition=full","pubTime":"2024-09-19 21:32","pubTimestamp":1726752727,"startTime":"0","endTime":"0","summary":"北京时间2024年09月19日21时32分，Vanda Pharmaceuticals Inc.股票出现异动，股价急速跳水9.09%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.81%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409192132079f07f0b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409192132079f07f0b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"2468717595","title":"万达生物制药(VNDA)盘前跌8.28% 公司药物tradipitant申请遭美FDA拒绝","url":"https://stock-news.laohu8.com/highlight/detail?id=2468717595","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468717595?lang=zh_cn&edition=full","pubTime":"2024-09-19 20:59","pubTimestamp":1726750795,"startTime":"0","endTime":"0","summary":"金吾财讯 | 万达生物制药(VNDA)盘前股价走低，暂跌8.28%，报4.54美元。据媒体报道，美国食品和药物管理局（FDA）拒绝批准 公司的药物用于治疗胃瘫痪症状。公司正寻求该健康监管机构对其药物 tradipitant 的批准，用于治疗胃轻瘫，这是一种以胃排空延迟为特征的疾病。该病症伴随严重恶心、呕吐和难以完成正常餐食等症状。健康监管机构此前对 tradipitant 施加了部分临床限制，阻止超过 12 周的试验。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/ZjBiNzEwNDA3MTQ3NjM4OTQ3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZjBiNzEwNDA3MTQ3NjM4OTQ3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"280078","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"2468573529","title":"BUZZ-美国 FDA 拒绝批准 Vanda Pharma 的新药上市，该公司股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2468573529","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468573529?lang=zh_cn&edition=full","pubTime":"2024-09-19 19:50","pubTimestamp":1726746637,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    9月19日 - ** 制药商旺达制药  股价盘前下跌10.9%，至4.41美元** 该公司称，美国食品和药物管理局（FDA）拒绝了 (link) 批准其胃麻痹药物替替匹坦的申请。** 该公司称 FDA 建议万达进行更多研究** 将继续寻求批准该药物用于治疗胃瘫，胃瘫的特点是胃排空延迟 ** 计划在今年晚些时候单独提交用于预防晕车呕吐的替替匹坦的上市申请** 该公司股价今年累计上涨 17.3%，而纳斯达克生物技术指数  上涨 11.3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"2468652070","title":"更新版 1-美国 FDA 拒绝批准旺达的胃麻痹药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2468652070","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468652070?lang=zh_cn&edition=full","pubTime":"2024-09-19 19:29","pubTimestamp":1726745379,"startTime":"0","endTime":"0","summary":"     路透9月19日 - 美国食品和药物管理局拒绝批准万达制药公司  治疗胃麻痹症状的药物。该公司股价在盘前交易中下跌约14%，至4.26美元。万达正在寻求卫生监管机构批准该公司的药物tradipitant用于治疗胃瘫，胃瘫是一种以胃排空延迟为特征的疾病。万达公司从礼来  公司获得了替替匹坦的授权，目前也在研究它对晕车症的治疗作用。卫生监管机构对替替匹坦实施了部分临床搁置，禁止进行超过12周的试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B1BXHZ80.USD","IE00BFTCPJ56.SGD","LU0471298777.SGD","LU1061106388.HKD","LU0256863811.USD","BK4007","LU0289739699.SGD","LU1023059063.AUD","IE0004445239.USD","BK4533","LU0238689110.USD","LU1064131342.USD","IE00B2B36J28.USD","BK4588","LU0320765059.SGD","LU0471298694.HKD","LU0354030511.USD","VNDA","LU0708995401.HKD","LU0114720955.EUR","IE00B4R5TH58.HKD","LU0823416689.USD","IE0002141913.USD","LU0943347566.SGD","BK4585","LU0672654240.SGD","BK4516","LU0689472784.USD","IE00BK4W5M84.HKD","LU0094547139.USD","LU0820561818.USD","LU0079474960.USD","LU0061475181.USD","IE00BJT1NW94.SGD","BK4139","LU0106261372.USD","LU0006306889.USD","LU0354030438.USD","LU1280957306.USD","LU0882574055.USD","LU0466842654.USD","IE0009355771.USD","LU0820561909.HKD","LU1267930730.SGD","IE00BJJMRZ35.SGD","LU0122379950.USD","LU0417517546.SGD","LLY","LU0097036916.USD","GB00BDT5M118.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vandapharma.com","stockEarnings":[{"period":"1week","weight":0.0369},{"period":"1month","weight":-0.0245},{"period":"3month","weight":0.0369},{"period":"6month","weight":-0.219},{"period":"1year","weight":0.2416},{"period":"ytd","weight":0.1327}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vanda Pharmaceuticals Inc.于2002年在特拉华州注册成立。该公司是一家全球领先的生物制药公司，专注于创新疗法的开发和商业化，以解决高度未满足的医疗需求并改善患者的生活。该公司努力推进新的方法，通过负责任的创新将重要的新药推向市场。该公司致力于在药物发现、临床试验和产品的商业定位中使用支持健全科学的技术，包括遗传学和基因组学。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.022786},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.012763},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.017891},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.012406},{"month":5,"riseRate":0.5,"avgChangeRate":0.809984},{"month":6,"riseRate":0.578947,"avgChangeRate":0.046161},{"month":7,"riseRate":0.421053,"avgChangeRate":-0.029968},{"month":8,"riseRate":0.421053,"avgChangeRate":-0.00847},{"month":9,"riseRate":0.263158,"avgChangeRate":-0.053183},{"month":10,"riseRate":0.473684,"avgChangeRate":-0.006033},{"month":11,"riseRate":0.631579,"avgChangeRate":0.044841},{"month":12,"riseRate":0.526316,"avgChangeRate":0.021125}],"exchange":"NASDAQ","name":"万达生物制药","nameEN":"Vanda Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万达生物制药(VNDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万达生物制药(VNDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万达生物制药,VNDA,万达生物制药股票,万达生物制药股票老虎,万达生物制药股票老虎国际,万达生物制药行情,万达生物制药股票行情,万达生物制药股价,万达生物制药股市,万达生物制药股票价格,万达生物制药股票交易,万达生物制药股票购买,万达生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万达生物制药(VNDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万达生物制药(VNDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}